AstraZeneca reports positive Phase III lung cancer trial results
AstraZeneca’s DeLLphi-305 Phase III trial says a combination of Imfinzi with Amgen’s Imdelltra produced statistically significant, clinically meaningful overall survival improvement in ES-SCLC patients.
The DeLLphi-305 Phase III trial found that a combination of Imfinzi with Amgen's Imdelltra delivered a statistically significant and highly clinically meaningful improvement in overall survival in patients with ES-SCLC. The combination also delivered statistically significant and clinically meaningful benefit versus the comparator.